September 16, 2021
Bantam Pharmaceutical Completes $25 Million Seed Funding

Bantam Pharmaceutical Completes $25 Million Seed Funding to Finalize Preclinical Development and Prepare for First in Humans Trials IND Application Expected in Early 2022 for Its Lead Product BTM-3566 Company Establishes Operations in the Research Triangle Park NEWS PROVIDED BY Bantam Pharmaceutical, LLC Sep 16, 2021, 08:00 ET Bantam plans to submit its Investigational New […]

Read More
April 27, 2021
Bantam Pharmaceutical Appoints Industry Veteran

Bantam Pharmaceutical Appoints Industry Veteran Michael Stocum as President and Chief Executive Officer New York, N.Y. - April 27, 2021 —Bantam Pharmaceutical, a drug discovery, and development company targeting selective modulation of mitochondrial dynamics in cancer, announced today that it has named Michael Stocum, MS as President and Chief Executive Officer. Mr. Stocum succeeds the […]

Read More
August 2, 2020
Bantam Presents at the AACR Virtual Meeting: Advances in Malignant Lymphoma - August 2020
Read More
July 6, 2018
Bantam Presents at the Inaugural AACR Advances in Malignant Lymphoma Meeting - June 2018
Read More
July 6, 2017
Bantam Publication in Bioorganic & Medicinal Chemistry Letters - June 2017
Read More
We are an early mover in the field of mitochondrial homeostasis, using our pioneering science and unrivaled expertise in mitochondrial cellular biology to revolutionize oncology
We are seeking partners and additional investors to accelerate our clinical research and help bring novel cancer therapies closer to patients in need
Find Out More
Bantam is seeking partners and investors to drive rapid clinical development of our first-in-class molecule from First in Humans trials to clinical Proof of Concept.
CONTACT US
[email protected]
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram